<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260623069931N4</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-10-02</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Effect of Gamified Virtual Reality Exercise on Emotional Well-Being in Risk-Averse Older Women</public_title>
      <acronym></acronym>
      <scientific_title>A Gamified VR Exercise Approach for Advancing Emotional Health in Risk-Averse Older Women: An Interdisciplinary Examination Based on the Broaden-and-Build Theory</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-05-30</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>138</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/93712</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: After completion of the baseline assessments and confirmation of eligibility, participants will be randomly allocated to the intervention and control groups in a 1:1 ratio. Simple randomization will be performed at the individual level. The allocation sequence will be generated using a computer-generated random-number sequence by a researcher who will not be involved in participant recruitment or intervention delivery. Allocation will occur only after eligibility confirmation and completion of baseline assessments to reduce allocation bias, Blinding description: Due to the nature of the intervention, participants and researchers responsible for intervention delivery will not be blinded to group allocation. Outcome assessors responsible for collecting and evaluating questionnaire data at baseline, post-intervention, and the 30-day follow-up will be blinded to participants’ allocation to the intervention or control group. Participants will also be instructed not to disclose their group allocation or intervention type to the outcome assessors during assessments.</study_design>
      <phase>N/A</phase>
      <hc_freetext>High risk aversion in older women.</hc_freetext>
      <i_freetext>Intervention group: Participants will complete a 4-week gamified virtual reality exercise program consisting of 12 sessions (3 sessions per week), with each session lasting 30–40 minutes, using Pico 4 Enterprise headsets. Exercises will include balance activities in virtual environments, walking on virtual platforms, balancing on narrow pathways, and simulated gliding activities. Gamification elements will include progressive levels, scoring, immediate feedback, and achievement badges..</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
De-identified individual participant data, including baseline characteristics and primary and secondary outcome data, will be available after publication of the study results upon reasonable request from researchers. No personally identifiable information will be shared.

When:
From 6 months after publication of the study results until 5 years after publication.

To whom:
Academic and scientific researchers, upon reasonable request and approval by the principal investigator.

Conditions:
The data and documents will be used only for scientific and research purposes and related analyses. Applicants must provide the research purpose and proposed analysis plan. Access will be granted after approval by the principal investigator and under conditions that ensure participant confidentiality.

Where to obtain:
Requests should be submitted to Hossein Faridniya, Principal Investigator, by email. Contact telephone: +98 936 387 5989.

How to obtain:
Requests will be reviewed by the principal investigator. The research purpose, analysis plan, and confidentiality requirements will be assessed. If approved, de-identified data will be provided within 30 days.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hossein Faridniya</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>University of Tehran, Enghelab-e Eslami Square, Enghelab-e Eslami Ave.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۵۰۴۱۷۲۱۰۶۸۵۹</zip>
        <telephone>+98 21 5566 4102</telephone>
        <email>hossein.faridniya@ut.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hossein Faridniya</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>University of Tehran, Enghelab-e Eslami Square, Enghelab-e Eslami Ave.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۵۰۴۱۷۲۱۰۶۸۵۹۳۷۱۵</zip>
        <telephone>+98 936 387 5989</telephone>
        <email>hossein.faridniya@ut.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Women aged 60–80 years
Clinically verified high risk aversion
Scores above the predefined cut-off on the Health/Safety and Recreational domains of the DOSPERT scale
Sufficient literacy to complete the study questionnaires
Adequate physical health to perform light-to-moderate physical activity, confirmed by a physician
Willingness to participate and provision of written informed consent</inclusion_criteria>
      <agemin>60 years</agemin>
      <agemax>80 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Cardiovascular conditions that will prevent safe participation in the exercise program
Musculoskeletal or balance disorders that will prevent safe participation in the exercise program
Active major psychiatric conditions, such as psychosis or untreated major depression
A history of epilepsy or photosensitivity that will be incompatible with safe use of a virtual reality headset</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Participants will complete a 4-week gamified virtual reality exercise program consisting of 12 sessions (3 sessions per week), with each session lasting 30–40 minutes, using Pico 4 Enterprise headsets. Exercises will include balance activities in virtual environments, walking on virtual platforms, balancing on narrow pathways, and simulated gliding activities. Gamification elements will include progressive levels, scoring, immediate feedback, and achievement badges.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Overall happiness score measured using the Oxford Happiness Inventory (OHI). Timepoint: At baseline (before the intervention); immediately after the 4-week intervention; 30 days after the intervention (follow-up). Method of measurement: Oxford Happiness Inventory, consisting of 29 items.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Positive affect score measured using the Oxford Happiness Inventory. Timepoint: At baseline (before the intervention); immediately after the 4-week intervention; 30 days after the intervention (follow-up). Method of measurement: Oxford Happiness Inventory, consisting of 29 items.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-05-03</approval_date>
        <contact_name>Ethics Committee of the Sport Sciences Research Institute (SSRI)</contact_name>
        <contact_address>No. 3, 5th Alley, Mir Emad St., Ostad Motahari St. Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
